Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival

Oncologist

Volumn 20, Issue 5, 2015, Pages 546-553

  Kwon, Minsu ^a   Roh, Jong Lyel ^a   Song, Jihyun ^a   Lee, Sang Wook ^a   Kim, Sung Bae ^a   Choi, Seung Ho ^a   Nam, Soon Yuhl ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Head and neck squamous cell carcinoma; Metformin; Recurrence; Second primary cancer; Survival

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; METFORMIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DATA PROCESSING; DIABETES MELLITUS; DRUG EFFICACY; ENDOSCOPY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SECOND CANCER; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; RISK FACTOR; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DIABETES MELLITUS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 84929086892     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0426     Document Type: Article

References (24)

1. Zakikhani M, Dowling R, Fantus IG et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66: 10269-10273.
2. Pierotti MA, Berrino F, Gariboldi M et al. Targeting metabolism for cancer treatment and prevention: Metformin, an old drug with multifaceted effects. Oncogene 2013;32:1475-1487.
3. Yin M, Zhou J, Gorak EJ et al. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis. The Oncologist 2013;18: 1248-1255.
4. Margel D, Urbach DR, Lipscombe LL et al. Metformin use and all-cause and prostate cancerspecific mortality among men with diabetes. J Clin Oncol 2013;31:3069-3075.
5. Margel D, Urbach D, Lipscombe LL et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 2013;105:1123-1131.
6. Sandulache VC, Hamblin JS, Skinner HD et al. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. Head Neck 2014;36:1039-1043.
7. Klubo-Gwiezdzinska J, Costello J Jr., Patel A et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab 2013;98:3269-3279.
8. Hwang AL, Haynes K, Hwang WT et al. Metformin and survival in pancreatic cancer: A retrospective cohort study. Pancreas 2013;42:1054-1059.
9. Kim JW, Roh JL, Kim JS et al. (18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma. Br J Cancer 2013;109:2973-2979.
10. Edge SB, Byrd DR, Compton CC et al. AJCC Cancer Staging Manual. New York, NY: Springer-Verlag, 2010.
11. Hashibe M, Brennan P, Benhamou S et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007;99:777-789.
12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of acompeting risk. J AmStat Assoc 1999;94:496-509.
13. Barone BB, Yeh HC, Snyder CF et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus:Asystematic reviewandmetaanalysis. JAMA 2008;300:2754-2764.
14. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: A consensus report. Diabetes Care 2010;33:1674-1685.
15. Basen-Engquist K, Chang M. Obesity and cancer risk: Recent review and evidence. Curr Oncol Rep 2011;13:71-76.
16. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578.
17. Bowker SL, Yasui Y, Veugelers P et al. Glucoselowering agents and cancer mortality rates in type 2 diabetes: Assessing effects of time-varying exposure. Diabetologia 2010;53:1631-1637.
18. Begum NM, Nakashiro K, Kawamata H et al. Expression of peroxisome proliferator-activated receptor gamma and the growth inhibitory effect of its synthetic ligands in human salivary gland cancer cell lines. Int J Oncol 2002;20:599-605.
19. Nakashiro K, Begum NM, Uchida D et al. Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptorgamma. Oral Oncol 2003;39:855-861.
20. Tseng CH. Pioglitazone and oral cancer risk in patients with type 2 diabetes. Oral Oncol 2014;50: 98-103.
21. Kim J, Lim W, Kim EK et al. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptorpositive postmenopausal breast cancer (METEOR). BMC Cancer 2014;14:170.
22. Limesand KH, Chibly AM, Fribley A. Impact of targeting insulin-like growth factor signaling in head and neck cancers. Growth Horm IGF Res 2013;23: 135-140.
23. Kwon M, Roh JL, Song J et al. Noncancer health events as a leading cause of competing mortality in advanced head and neck cancer. Ann Oncol 2014;25:1208-1214.
24. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.